Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise for rare nerve disease recovery

NCT ID NCT04752566

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 23 times

Summary

This study tested a drug called eculizumab in 57 people with severe Guillain-Barré syndrome (GBS), a rare condition where the immune system attacks nerves, causing muscle weakness and paralysis. Participants received either eculizumab or a placebo alongside standard treatment. The goal was to see if the drug helped them regain the ability to walk independently faster. The trial took place only in Japan and has been completed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GUILLAIN-BARRE SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Bunkyō City, 113-8519, Japan

  • Research Site

    Chiba, 260-0877, Japan

  • Research Site

    Fukuoka, 814-0180, Japan

  • Research Site

    Hiroshima, 730-8518, Japan

  • Research Site

    Kagoshima, 890-8520, Japan

  • Research Site

    Kawagoe-shi, 350-8550, Japan

  • Research Site

    Kawasaki-shi, 216-8511, Japan

  • Research Site

    Kitakyushu-shi, 807-8555, Japan

  • Research Site

    Kobe, 650-0047, Japan

  • Research Site

    Kumamoto, 860-8556, Japan

  • Research Site

    Kurashiki-shi, 710-8602, Japan

  • Research Site

    Matsumoto-shi, 390-8621, Japan

  • Research Site

    Mitaka-shi, 181-8611, Japan

  • Research Site

    Nagoya, 466-8560, Japan

  • Research Site

    Niigata, 951-8520, Japan

  • Research Site

    Nishinomiya-shi, 663-8501, Japan

  • Research Site

    Sapporo, 060-8648, Japan

  • Research Site

    Sayama, 589-8511, Japan

  • Research Site

    Sendai, 983-8520, Japan

  • Research Site

    Shimotsuga-gun, 321-0293, Japan

  • Research Site

    Ube-shi, 755-8505, Japan

  • Research Site

    Yokohama, 236-0004, Japan

Conditions

Explore the condition pages connected to this study.